These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 709531)

  • 21. [Diffuse malignant pleural mesothelioma].
    Katsuragi N; Shiraishi Y; Kita H; Toishi M; Miyasaka Y; Tanaka S
    Kyobu Geka; 2007 Jan; 60(1):35-9. PubMed ID: 17249536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
    Pagan V; Ceron L; Paccagnella A; Pizzi G
    J Cardiovasc Surg (Torino); 2006 Oct; 47(5):595-601. PubMed ID: 17033611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffuse malignant mesothelioma of the pleura--intrapleural treatment with doxorubicin.
    Matzel W; Büchel O
    Arch Geschwulstforsch; 1987; 57(3):209-18. PubMed ID: 3619593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.
    Henss H; Fiebig HH; Schildge J; Arnold H; Hasse J
    Onkologie; 1988 Jun; 11(3):118-20. PubMed ID: 3045724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of pirarubicin in malignant pleural mesothelioma.
    Kaukel E; Koschel G; Gatzemeyer U; Salewski E
    Cancer; 1990 Aug; 66(4):651-4. PubMed ID: 2386894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy of malignant mesothelioma.
    Spremulli E; Wampler G; Regelson W; Borochovitz D; Hardy T
    Cancer; 1977 Nov; 40(5):2038-45. PubMed ID: 336176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.
    Ardizzoni A; Rosso R; Salvati F; Fusco V; Cinquegrana A; De Palma M; Serrano J; Pennucci MC; Soresi E; Crippa M
    Cancer; 1991 Jun; 67(12):2984-7. PubMed ID: 2044044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
    Samson MK; Wasser LP; Borden EC; Wanebo HJ; Creech RH; Phillips M; Baker LH
    J Clin Oncol; 1987 Jan; 5(1):86-91. PubMed ID: 3543239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
    Fizazi K; Doubre H; Le Chevalier T; Riviere A; Viala J; Daniel C; Robert L; Barthélemy P; Fandi A; Ruffié P
    J Clin Oncol; 2003 Jan; 21(2):349-54. PubMed ID: 12525529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors for 100 patients with malignant pleural mesothelioma.
    Gonlugur U; Gonlugur TE
    Arch Environ Occup Health; 2010; 65(2):65-9. PubMed ID: 20439224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin.
    Arrieta O; Medina LA; Estrada-Lobato E; Ramírez-Tirado LA; Mendoza-García VO; de la Garza-Salazar J
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):211-5. PubMed ID: 24817602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evolutive patterns of diffuse pleural mesothelioma (author's transl)].
    de Lajartre AY; Tayot J; de Lajartre M; Fondimare A
    Rev Fr Mal Respir; 1979; 7(3):277-90. PubMed ID: 115073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of intravenous Doxil in malignant pleural mesothelioma.
    Oh Y; Perez-Soler R; Fossella FV; Glisson BS; Kurie J; Walsh GL; Truong M; Shin DM
    Invest New Drugs; 2000 Aug; 18(3):243-5. PubMed ID: 10958592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
    Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
    J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
    Ried M; Potzger T; Braune N; Neu R; Zausig Y; Schalke B; Diez C; Hofmann HS
    Eur J Cardiothorac Surg; 2013 Apr; 43(4):801-7. PubMed ID: 22885228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy for malignant pleural mesothelioma.
    Janne PA
    Clin Lung Cancer; 2003 Sep; 5(2):98-106. PubMed ID: 14596692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete response and long-term survival in malignant pleural mesothelioma: case report.
    Takanen S; Resuli B; Graziano V; Parisi A; Lisi R; Raffetto N; Tombolini V
    Anticancer Res; 2012 Apr; 32(4):1485-7. PubMed ID: 22493390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Malignant pleural mesothelioma].
    Kawamata O; Kondu Y; Murata T; Uetsuka H; Uda M; Nakai H; Ohta T
    Kyobu Geka; 2007 Jan; 60(1):31-4. PubMed ID: 17249535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience.
    Lerner HJ; Schoenfeld DA; Martin A; Falkson G; Borden E
    Cancer; 1983 Dec; 52(11):1981-5. PubMed ID: 6627213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.